Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-17

At first glance, it looks nothing new however if we dig a little bit two new information are here. Firstly almost 78% data so far has been analysed, trial continuation after read out does mean something isn’t it? I see like agvhd, probability of achieving primary endpoint has increased if remaining data’s outcome is consistent. Secondly, After 465 readout trial continuation reveals the “overwhelming efficacy has not been achieved “ otherwise it would have stopped at this point. Nonetheless, SI and board understood this so they made an understanding with FDA to conduct parallel trial including same number of patients.( i’m bit unsure exactly about number). Also they are looking to leverage data readout from NIH conducted trial. Overall, it is positive development and some kind of validation amidst the frustration and agony of some of the shareholders - including me. I know market is inefficient however the way share price builds momentum before announcement is very astonishing to me. How would someone even know when announcement is happening? Isn’t it detrimental against retail investors? I’m pretty much new to investment so seeing this trend particularly in MSB suggest dissemination of information isn’t efficient. And seems like this trend will continue.